AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03312413
Drug: Dexmedetomidine Hydrochloride
RxNorm normalized name: Dexmedetomidine Hydrochloride
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine Hydrochloride 0.7 μg·kg-1·h-1 will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery
Trial: NCT01260818
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 g Tranexamic Acid mixed with 100ml saline are kept in wound for 2 hours before drainage is opened postoperatively
Trial: NCT00543231
Drug: G3139, Oblimersen sodium, Bcl-2 antisense oligonucleotide
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02539459
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 mg tablets
Trial: NCT04176133
Drug: Entolimod
RxNorm normalized name: Entolimod
DrugBank: Entolimod (DB12304)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) single dose administration. Entolimod is provided as a sterile, clear, colorless or slightly yellow liquid for IM injection.
Trial: NCT02271360
Drug: Cabergoline
RxNorm normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tab/day Cabergoline( 0.5 mg) will be given at day of HCG injection and for 8 days
Trial: NCT00132275
Drug: Amoxicillin potassium clavulanate
RxNorm normalized name: amoxicillin / clavulanate
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00781105
Drug: Telbivudine
RxNorm normalized name: Telbivudine
DrugBank: Telbivudine (DB01265)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 600 mg/day, oral tablets, once daily, 52 weeks
Trial: NCT00995839
Drug: continuous infusion of terlipressin
DrugBank: Terlipressin (DB02638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous continuous infusion of terlipressin 1 µg•kg-1•h-1 for 6 hrs
Trial: NCT00995839
Drug: Arginine vasopressin
RxNorm normalized name: 1-deamino-8-D-arginine vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous continuous infusion of arginine vasopressin 0.04 UI•min-1 for 6 hrs
Trial: NCT00995839
Drug: terlipressin bolus administration
DrugBank: Terlipressin (DB02638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous terlipressin bolus administration at the dose of 0.5 mg
Trial: NCT00443170
Drug: GSK626616, placebo, midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00447564
Drug: Probuphine
RxNorm normalized name: Probuphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4 implants
Trial: NCT03242967
Drug: Vadadustat
RxNorm normalized name: vadadustat
DrugBank: Vadadustat (DB12255)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Oral tablet
Trial: NCT03242967
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: subcutaneous or intravenous
Trial: NCT02145468
Drug: Losmapimod 7.5 mg twice daily
DrugBank: Losmapimod (DB12270)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive Losmapimod 7.5 mg as film-coated, round, plain faced tablets.
Trial: NCT00673621
Drug: Salbutamol (Albuterol)
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 puff = 200 mcg total dose
Trial: NCT01640639
Drug: Thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thalidomide, pill, 50 mg, once p.d., 6 weeks
Trial: NCT01609062
Drug: BMN 110
RxNorm normalized name: DNA (synthetic adeno-associated virus 5 vector BMN 270 human blood-coagulation factor VIII SQ variant-specifying)
DrugBank: Tipapkinogene sovacivec (DB06239)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly IV infusions of BMN 110 at 2.0 mg/kg/week over a period of approximately 4 hours per infusion for up to 192 weeks.
Trial: NCT01609062
Drug: BMN 110
RxNorm normalized name: DNA (synthetic adeno-associated virus 5 vector BMN 270 human blood-coagulation factor VIII SQ variant-specifying)
DrugBank: Tipapkinogene sovacivec (DB06239)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly IV infusions of BMN 110 at 4.0 mg/kg/week over a period of approximately 4 hours per infusion for 27 weeks, and will eventually transition to 2.0 mg/kg/week for up to an additional 166 weeks.
Trial: NCT00680992
Drug: Denosumab
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 120 mg administered subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study days 8 and 15.
Trial: NCT02498912
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fludarabine dose 25-30 mg/m2 x 3 days
Trial: NCT00316017
Drug: 7.5% hypertonic saline/6% Dextran-70 (HSD)
DrugBank: Dextran (DB09255)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 cc dose given as a one-time intravenous (IV) bolus in the pre-hospital setting.
Trial: NCT02445053
Drug: ivacaftor
RxNorm normalized name: Ivacaftor
DrugBank: Ivacaftor (DB08820)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02789644
Drug: Ursodeoxycholic Acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 1: Ursodeoxycholic acid 400mg or 800mg qd Day 2 to 15: Ursodeoxycholic acid 200mg bid
Trial: NCT02834247
Drug: TAK-659
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-659 Tablets.
Trial: NCT02834247
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab intravenous infusion.
Trial: NCT04152057
Drug: Pyrotinib Maleate Tablets
RxNorm normalized name: maleate
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg/d,po qd,q3w, 4 cycles
Trial: NCT04152057
Drug: Albumin Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 125mg/m2,ivggt,d1,q3w,4 cycles.
Trial: NCT04152057
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The first week load dose 4mg / kg, followed by 2mg / kg per week, d1,ivggt,q3w,4 cycles.
Trial: NCT01468181
Drug: Biguanides (BG)
RxNorm normalized name: biguanide
DrugBank: Biguanide (DB13100)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biguanides is a pre-study prescribed dose and is not being provided as part of the trial.
Trial: NCT01314781
Drug: solifenacin
RxNorm normalized name: Solifenacin
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: solifenacin 5mg tablet once daily
Trial: NCT01683994
Drug: Cabozantinib
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Assigned dose given daily during each 21 day cycle. Treatment may continue until disease progression or intolerable toxicity.
Trial: NCT01468181
Drug: Thiazolidinedione (TZD)
RxNorm normalized name: (±)-5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione
DrugBank: 2,4-thiazolidinedione (DB11898)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TZD is a pre-study prescribed dose and is not being provided as part of the trial.
Trial: NCT00659555
Drug: pazopanib eye drops
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pazopanib will be administered as eye drop solution via topical ocular route. Pazopanib eye drops will be available as white, colorless solution.
Trial: NCT00659555
Drug: Ketoconozole tablets
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoconozole will be administered as tablets via oral route. Ketoconozole tablets will be present as white, rounded, scored tablets
Trial: NCT01683994
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75mg/m\^2 intravenous (IV) over approximately 60 minutes on cycle 1 day 1 and repeated every 21 days until disease progression or intolerable toxicity.
Trial: NCT01683994
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg by mouth (PO) twice a day during each 21 day cycle until disease progression or intolerable toxicity.
Trial: NCT02419547
Drug: Versed
RxNorm normalized name: Versed
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Phase 1: Standard induction of controled sedation with intravenous agent then programed stimulation to induce ventricular tachycardia
Trial: NCT02419547
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phase 2: Standard induction of GETA with intravenous agent then programed stimulation to induce ventricular tachycardia
Trial: NCT02419547
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phase 3: Standard induction of GETA with inhalent agent then programed stimulation to induce ventricular tachycardia
Trial: NCT02341144
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00763997
Drug: dipyrone
RxNorm normalized name: Dipyrone
DrugBank: Metamizole (DB04817)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyrone is given in the operation room with 2,5 g intravenously, followed by an oral regime of 4x1g on the ward
Trial: NCT00538317
Drug: tirofiban
RxNorm normalized name: Tirofiban
DrugBank: Tirofiban (DB00775)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bolus of 25 µg/kg lasting 3 minutes then 18h to 24h perfusion of 0.15 µg/kg/min
Trial: NCT00515723
Drug: risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: randomized to 12 week trial of risperidone.
Trial: NCT00515723
Drug: olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: randomized to 12 week trial of olanzapine.
Trial: NCT00515723
Drug: quetiapine
RxNorm normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: randomized to 12 week trial of quetiapine.
Trial: NCT00515723
Drug: ziprasidone
RxNorm normalized name: Ziprasidone
DrugBank: Ziprasidone (DB00246)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: randomized to 12 week trial of ziprasidone.
Trial: NCT00005945
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT
Trial: NCT00005945
Drug: daunorubicin hydrochloride
RxNorm normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03776539
Drug: ELX-02
RxNorm normalized name: ELX-02
DrugBank: ELX-02 (DB15080)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ELX-02 is a synthetic, designer eukaryotic ribosomal specific glycoside (ERSG) optimized as a translational read-through drug. All groups will get the same treatment.
Trial: NCT02957032
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will be treated with cytarabine (5 mg twice daily s.c. for 10 days). Treatment will be repeated every 28 days for up to three cycles.
Trial: NCT00005945
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT01934790
Drug: Radium-223 dichloride (Xofigo, BAY88-8223)
DrugBank: Radium Ra 223 dichloride (DB08913)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants received intravenous (IV) injection of radium-223 dichloride 50 kBq/kg body weight every 4 weeks up to 6 injections.
Trial: NCT03442023
Drug: Chlorhexidine gluconate at 2%
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mouth Rinse with Chlorhexidine gluconate at 2% every 12 hours, one week.
Trial: NCT03442023
Drug: Chlorhexidine gluconate at 0.12%
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mouth Rinse with Chlorhexidine gluconate at 0.12% every 12 hours, one week.
Trial: NCT00164177
Drug: HalfLytely
RxNorm normalized name: HalfLytely and Bisacodyl
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04616716
Drug: FMTN
RxNorm normalized name: Fluvoxamine
DrugBank: Fluvoxamine (DB00176)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of FMTN after high-fat meal,low-fat meal and fast
Trial: NCT00005945
Drug: pegaspargase
RxNorm normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IM
Trial: NCT00576563
Drug: FDG
RxNorm normalized name: 18F-FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: contrast medium
Trial: NCT05216822
Drug: Racecadotril
RxNorm normalized name: racecadotril
DrugBank: Racecadotril (DB11696)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: racecadotril (dose of 1.5 mg/kg/day, an oral single daily dose for three days
Trial: NCT00507403
Drug: infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00005945
Drug: thioguanine
RxNorm normalized name: Thioguanine
DrugBank: Tioguanine (DB00352)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00005945
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01486602
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV
Trial: NCT01486602
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV
Trial: NCT00777764
Drug: Cohort I
RxNorm normalized name: IOBENGUANE I 123
DrugBank: Iobenguane (DB06704)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In sterile water for injection (SWFI), full concentration and 1:1000, 1:100, 1:10 dilutions of 125 mg/mL of standard solution of omalizumab and its excipients. Skin prick test of each dilution concentration of 1:1000, 1:100, 1:10 and full concentration and Intradermal tests of each dilution concentration of 1:1000, 1:100 and 1:10 were followed by 20 minutes of observation. For the skin prick test, participants were tested initially with positive control (histamine 6 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration.~For the intradermal test, participants were tested initially with positive control (histamine 0.1 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration.~Dilutions of omalizumab and its excipients were in SWFI.
Trial: NCT00022581
Drug: thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT03880253
Drug: CTP-692
RxNorm normalized name: CTP-SOMATROPIN FUSION PROTEIN
DrugBank: Somatrogon (DB14960)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Placebo or CTP-692
Trial: NCT04018274
Drug: PF-06651600
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg by mouth (PO) once daily (QD)
Trial: NCT00176982
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02748889
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard chemotherapy
Trial: NCT02748889
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard chemotherapy
Trial: NCT00387426
Drug: sunitinib malate
RxNorm normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT02218606
Drug: Abiraterone acetate 1000 mg po daily
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02218606
Drug: Cabazitaxel 25 mg/m2 IV
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02218606
Drug: prednisone 5 mg po BID
RxNorm normalized name: prednisone 5 MG
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04292704
Drug: Clotrimazole
RxNorm normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clotrimazole vaginal tablets
Trial: NCT04056988
Drug: Perflutren Lipid Microsphere
RxNorm normalized name: perflutren lipid microspheres
DrugBank: Perflutren (DB00556)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perflutren lipid microsphere preparation is an ultrasound contrast agent. Ultrasound contrast agents are used to help provide a clear picture during ultrasound.
Trial: NCT03633747
Drug: Propranolol Hydrochloride
RxNorm normalized name: Propranolol Hydrochloride
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral propranolol hydrochloride tablets are administration for 6 months at dose of 1.5 mg/kg or the maximum dose tolerable.
Trial: NCT00306813
Drug: Revlimid
RxNorm normalized name: Revlimid
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00003397
Drug: carmustine
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003397
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003397
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003397
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003397
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003397
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003397
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00961467
Drug: Revlimid, Melphalan, Prednisone, Thalidomide
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thalidomide was administered at 50 mg/day.
Trial: NCT00961467
Drug: Revlimid, Melphalan, Prednisone, Thalidomide
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thalidomide was administered at 100 mg/day.
Trial: NCT02706405
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04394377
Drug: Group 2: control group with enoxaparin 40mg/d
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual standard of care and currently have no indication of full anticoagulation.
Trial: NCT05190783
Drug: Formocresol
RxNorm normalized name: Formocresol
DrugBank: Cresol (DB11143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mixture of formalin, cresol and glycerine used for fixation of pulp tissues
Trial: NCT05190783
Drug: MTA
RxNorm normalized name: HMTA
DrugBank: 5'-S-methyl-5'-thioadenosine (DB02282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: material used for pulp regeneration, direct and indirect pulp capping
Trial: NCT02304705
Drug: Sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg three times daily by mouth for 90 days
Trial: NCT00204659
Drug: Rituximab + CHOP chemotherapy
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: standard Rituximab + CHOP chemo-immunotherapy
Trial: NCT01603420
Drug: Luteinizing hormone-releasing hormone (LHRH)
DrugBank: Triptorelin (DB06825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Androgen suppression therapy using luteinizing hormone-releasing hormone (LHRH) agonists such as leuprolide, goserelin, buserelin, triptorelin.
Trial: NCT01933243
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will take 4 capsules daily
Trial: NCT04020185
Drug: Immune checkpoint inhibitor (ICI)
RxNorm normalized name: Anti-tim3 checkpoint inhibitor mbg453
DrugBank: Sabatolimab (DB16322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered according to product label
Trial: NCT01603420
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 20mg/m2 IV every 7 days x 8 weeks.
Trial: NCT00330252
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given intravenously on day 1 of every week for eight weeks (or 16 weeks)
Trial: NCT00330252
Drug: Alemtuzumab
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug: Alemtuzumab Dosage will vary during Phase I of trial: Given intravenously on days 1, 3, and 5 for weeks one and two, on days 1 and 4 for weeks three and four and on day 1 for weeks five through eight. Participants may receive either one eight-week course of treatment or two eight-week courses of treatment (16 weeks).